KTX-545

**KTX-545** is an investigational **oral small-molecule targeted protein degrader** developed by **Kymera Therapeutics** that selectively degrades **interleukin-1 receptor-associated kinase 4**. In Kymera preclinical presentations, KTX-545 is described as a potent and selective IRAK4 degrader that suppresses **TLR** and **IL-1 receptor** pathway signaling more broadly than conventional IRAK4 kinase inhibitors because degradation removes both the **kinase** and **scaffolding** functions of IRAK4. Reported preclinical activity includes inhibition of NF-kB p65 and MAPK signaling, broad cytokine suppression in immune-cell assays, and exploration in inflammatory and autoimmune settings, while oncology presentations used KTX-545 mainly as a selective IRAK4 degrader comparator versus dual IRAK4 and IMiD substrate degraders such as KT-413. No evidence was identified that KTX-545 advanced into clinical development, marketing, or branded commercialization.